CA-ANDERSEN-GLOBAL
26.2.2021 11:53:13 CET | Business Wire | Pressemeddelelse
Andersen Global udvider til St. Vincent og Grenadinerne med samarbejdsfirmaet Baptiste & Co. Law Firm, og styrker dermed sin caribiske platform og tilføjer yderligere dækning i den sydlige del af regionen.
Baptiste & Co. Law Firm blev grundlagt i 1986 af administrerende partner, René M. Baptiste, som har mere end 40 års erfaring. Ud over grundlæggelsen af firmaet omfatter Renés bedrifter fuldgyldigt medlemskab af advokatsamfundet i St. Vincent og Grenadinerne, Antigua og Barbuda, Saint Kitts og Nevis; offentliggjorte artikler i tidsskriftet International Finance ; to tjenesteperioder som folkevalgt medlem af parlamentet og minister i St. Vincent og Grenadinerne; samt rollen som formand for organisationen af østlige caribiske staters forsamling. Derudover har hun mere end 50 års offentlig tjeneste, hvilket har resulteret i anerkendelse fra Hendes Majestæt Dronning Elizabeth II i form af udnævnelse til Commander of Saint Michael and Saint George (CMG) for tjenester inden for jura, international finans, kultur og politik.
Baptiste & Co. er et full service-advokatfirma, der er specialiseret i konkurs og insolvens, handelsret, kontrakter, familieret, ejendomsret, ejendomsplanlægning, intellektuel ejendomsret (varemærker) og fast ejendom. Firmaet, der er beliggende i Kingstown, yder juridisk rådgivning og tjenester til enkeltpersoner, offentlige og private virksomheder, kreditforeninger, banker, forsikringsselskaber og rederier, samt udenlandske regeringer og statslige virksomheder. Derudover leverer firmaets advokater tjenester i flere retskredse på naboøer og er strategisk placeret for at hjælpe med grænseoverskridende tjenester i ethvert område af firmaets praksisområder.
"Vi er glade for at samarbejde med ligesindede, der forstår og efterlever værdier bestående af gennemsigtighed og uafhængighed," sagde René. "Vores firma har forpligtet sig til at levere omfattende, uovertrufne løsninger, der overgår kundernes forventninger. At samarbejde med Andersen Globals medlemsfirmaer og samarbejdsfirmaer forbedrer vores evne til at levere synergistiske tjenester til vores kunder på både lokalt og internationalt niveau."
Bestyrelsesformand for Andersen Global og administrerende direktør for Andersen, Mark Vorsatz, tilføjede: "Vi har udviklet en stærk tilstedeværelse i Caribien og vil fortsætte med at tilføje bredde og dybde til vores platform i regionen. René og hendes teams engagement i forvaltning, mange års erfaring og viden om lokale og internationale retskredse adskiller dem fra andre firmaer på markedet. Tilføjelsen af Baptiste & Co. er endnu et vigtigt link til vores strategi i regionen."
Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer bestående af skatte- og juraeksperter fra hele verden. Efter at være blevet etableret i 2013 af det amerikanske medlemsfirma Andersen Tax LLC har Andersen Global nu over 7.000 eksperter globalt og er repræsenteret på mere end 255 lokaliteter via sine medlems- og samarbejdsfirmaer.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210226005233/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 14:05:00 CEST | Press release
Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burdenEnpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standardsELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 14:00:00 CEST | Press release
Celebrating the ecommerce leaders from Michael Kors and Gymshark shaping the future of fraud prevention and risk management Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are:Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 14:00:00 CEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
